Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
Results of a double-blind, placebo-controlled, fixed-dose ER for once-daily OROS® Hydromorphone in patients with moderate to severe pain associated with chronic osteoarthritis